

Ian N Bruce

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8639870/ian-n-bruce-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

244 papers	24,735 citations	63 h-index	155 g-index
300 ext. papers	28,909 ext. citations	5.7 avg, IF	7.53 L-index

#	Paper	IF	Citations
244	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	6
243	Longitudinal analysis of urinary proteins in lupus nephritis - A pilot study.. <i>Clinical Immunology</i> , 2022 , 236, 108948	9	0
242	Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. <i>Lancet Rheumatology</i> , 2022 ,	14.2	2
241	Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	6
240	Pregnancy outcomes of a joint obstetric and rheumatology clinic in a tertiary centre: a 2-year retrospective study of 98 pregnancies.. <i>Rheumatology Advances in Practice</i> , 2022 , 6, rkac026	1.1	0
239	Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial. <i>Lupus Science and Medicine</i> , 2022 , 9, e000584	4.6	0
238	Flares in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2021 , 60, 3262-3267	3.9	2
237	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021 , 73, 1231-1235	4.7	10
236	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	4
235	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	7
234	Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. <i>Rheumatology</i> , 2021 , 60, 617-628	3.9	8
233	A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment. <i>Rheumatology</i> , 2021 , 60, 3747-3759	3.9	9
232	Evolving concepts in systemic lupus erythematosus damage assessment. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 307-308	8.1	3
231	What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials. <i>Arthritis and Rheumatology</i> , 2021 , 73, 2059-2068	9.5	2
230	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021 , 30, 1283-1288	2.6	2
229	Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. <i>Rheumatology</i> , 2021 , 60, 5397-5407	3.9	10
228	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021 , 73, 2293-2302	9.5	2

227	Accelerated atherosclerosis and cardiovascular disease in systemic lupus erythematosus. <i>Revista Colombiana De Reumatología</i> , 2021 , 28, 21-30	0.2	1
226	The role of antirheumatics in patients with COVID-19. <i>Lancet Rheumatology, The</i> , 2021 , 3, e447-e459	14.2	19
225	Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models. <i>Arthritis Research and Therapy</i> , 2021 , 23, 203	5.7	0
224	Translating research into clinical practice: quality improvement to halve non-adherence to methotrexate. <i>Rheumatology</i> , 2021 , 60, 125-131	3.9	0
223	Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e101-e110	14.2	3
222	BSR guideline on the management of adults with systemic lupus erythematosus (SLE) 2018: baseline multi-centre audit in the UK. <i>Rheumatology</i> , 2021 , 60, 1480-1490	3.9	2
221	Estimation of the burden of shielding among a cross-section of patients attending rheumatology clinics with SLE-data from the BSR audit of systemic lupus erythematosus. <i>Rheumatology</i> , 2021 , 60, 1474-1479	3.9	6
220	Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	1
219	The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	1
218	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , 2021 , 60, 4737-4747	3.9	5
217	Differential levels of IFN γ subtypes in autoimmunity and viral infection. <i>Cytokine</i> , 2021 , 144, 155533	4	5
216	Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the PRe-clinical EValuation of Novel Targets in RA (PREVeNT-RA) Cohort. <i>Arthritis Research and Therapy</i> , 2021 , 23, 203	5.7	1
215	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	5
214	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , 2020 ,	4.7	2
213	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1734-1740	9.5	7
212	Differential analysis of serum and urine S100 proteins in juvenile-onset systemic lupus erythematosus (jSLE). <i>Clinical Immunology</i> , 2020 , 214, 108375	9	9
211	The challenges in data integration - heterogeneity and complexity in clinical trials and patient registries of Systemic Lupus Erythematosus. <i>BMC Medical Research Methodology</i> , 2020 , 20, 164	4.7	5
210	Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts. <i>Lancet Rheumatology, The</i> , 2020 , 2, e99-e109	14.2	16

209	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020 , 72, 1800-1808	4.7	7
208	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020 , 72, 658-666	9.5	11
207	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020 , 106, 102340	15.5	15
206	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 356-362	2.4	18
205	Trial of Anifrolumab in Active Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2020 , 382, 211-221	59.2	333
204	Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians. <i>Lancet Rheumatology, The</i> , 2020 , 2, e735-e736	14.2	3
203	Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment. <i>RMD Open</i> , 2020 , 6,	5.9	7
202	Generating evidence to inform health technology assessment of treatments for SLE: a systematic review of decision-analytic model-based economic evaluations. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	1
201	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2020 , 47, 72-81	4.1	21
200	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020 , 72, 67-77	9.5	18
199	Probabilistic Approaches to Overcome Content Heterogeneity in Data Integration: A Study Case in Systemic Lupus Erythematosus. <i>Studies in Health Technology and Informatics</i> , 2020 , 270, 387-391	0.5	
198	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2019 , 46, 492-500	4.1	7
197	Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles. <i>Arthritis Research and Therapy</i> , 2019 , 21, 147	5.7	8
196	Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. <i>Rheumatology</i> , 2019 , 58, 2162-2169	3.9	17
195	A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1437-1449	9.5	46
194	Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. <i>BMJ Open</i> , 2019 , 9, e025687	3	49
193	Clinical applications of machine learning algorithms: beyond the black box. <i>BMJ, The</i> , 2019 , 364, l886	5.9	109
192	Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changes. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 934-940	2.4	29

191	Rheumatoid arthritis reprograms circadian output pathways. <i>Arthritis Research and Therapy</i> , 2019 , 21, 47	5.7	18
190	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1297-1307	9.5	15
189	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019 , 58, 1259-1267	3.9	5
188	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019 , 71, 893-902	4.7	46
187	Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. <i>Trials</i> , 2019 , 20, 429	2.8	39
186	Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. <i>Lancet Rheumatology, The</i> , 2019 , 1, e208-e219	14.2	117
185	199 Baricitinib in patients with systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study 2019 ,		2
184	Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project. <i>Lupus Science and Medicine</i> , 2019 , 6, e000342	4.6	8
183	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1010-1012	2.4	4
182	Clinical Markers, Metrics, Indices, and Clinical Trials 2019 , 614-630		4
181	Current challenges in the development of new treatments for lupus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 729-735	2.4	20
180	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 281-289	9.5	31
179	Lupus community panel proposals for optimising clinical trials: 2018. <i>Lupus Science and Medicine</i> , 2018 , 5, e000258	4.6	43
178	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018 , 57, 677-687	3.9	20
177	Individuals living with lupus: findings from the LUPUS UK Members Survey 2014. <i>Lupus</i> , 2018 , 27, 681-687	2.6	26
176	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018 , 70, 1478-1487	4.7	36
175	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. <i>Rheumatology</i> , 2018 , 57, 14-18	3.9	23
174	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. <i>Rheumatology</i> , 2018 , 57, 470-479	4.9	47

173	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , 2018 , 57, e1-e45	3.9	150
172	Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients. <i>Arthritis Care and Research</i> , 2018 , 70, 98-103	4.7	18
171	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2018 , 392, 222-231	4.0	243
170	Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations. <i>Arthritis Research and Therapy</i> , 2018 , 20, 173	5.7	25
169	Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. <i>Rheumatology</i> , 2018 , 57, 1502-1503	3.9	7
168	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018 , 70, 1294-1302	4.7	13
167	Vitamin D and systemic lupus erythematosus - The hype and the hope. <i>Autoimmunity Reviews</i> , 2018 , 17, 19-23	13.6	33
166	136 Motor and cognitive fatigue in SLE is associated with mood and health-related quality of life (HRQoL) in patients with SLE: results from the Patient Reported Outcomes in Lupus (PRO-Lupus) study. <i>Rheumatology</i> , 2018 , 57,	3.9	1
165	Progression of subclinical and clinical cardiovascular disease in a UK SLE cohort: the role of classic and SLE-related factors. <i>Lupus Science and Medicine</i> , 2018 , 5, e000267	4.6	13
164	Drug-Induced Interstitial Lung Disease: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	117
163	QRISK3 improves detection of cardiovascular disease risk in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2018 , 5, e000272	4.6	15
162	Vitamin D treatment for connective tissue diseases: hope beyond the hype?. <i>Rheumatology</i> , 2017 , 56, 178-186	3.9	17
161	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 554-561	2.4	175
160	Microparticle subpopulations are potential markers of disease progression and vascular dysfunction across a spectrum of connective tissue disease. <i>BBA Clinical</i> , 2017 , 7, 16-22		20
159	The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. <i>Lupus</i> , 2017 , 26, 1051-1059	2.6	37
158	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. <i>RMD Open</i> , 2017 , 3, e000314	5.9	21
157	Can we identify who gets benefit or harm from mycophenolate mofetil in systemic lupus erythematosus? A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 47, 65-78	5.3	7
156	Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 47, 384-396	5.3	12

155	Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey. <i>Lupus Science and Medicine</i> , 2017 , 4, e0001734.6	14
154	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. <i>Rheumatology</i> , 2017 , 56, 1041-1043	3.9 1
153	Tartrate-Resistant Acid Phosphatase Deficiency in the Predisposition to Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017 , 69, 131-142	9.5 32
152	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , 2017 , 19, 287	5.7 1
151	Evaluation of non-contrast MRI biomarkers in lupus nephritis. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 954-958	2.2 4
150	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016 , 55, 252-62	3.9 210
149	Medication-related side effects in vasculitis: a patient self-report survey of awareness and reported uptake of protective therapy. <i>Rheumatology</i> , 2016 , 55, 185-6	3.9
148	Brief Report: Vitamin D Deficiency Is Associated With Endothelial Dysfunction and Increases Type I Interferon Gene Expression in a Murine Model of Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2929-2935	9.5 20
147	Cardiovascular risk and its modification in patients with connective tissue diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016 , 30, 81-94	5.3 9
146	A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. <i>Rheumatology</i> , 2016 , 55, 382-4	3.9 34
145	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1932-44	9.5 27
144	Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. <i>Lupus Science and Medicine</i> , 2016 , 3, e000143	4.6 40
143	Vitamin D improves endothelial dysfunction and restores myeloid angiogenic cell function via reduced CXCL-10 expression in systemic lupus erythematosus. <i>Scientific Reports</i> , 2016 , 6, 22341	4.9 44
142	Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. <i>Lupus</i> , 2016 , 25, 699-709	2.6 58
141	Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2016 , 68, 1505-13	4.7 38
140	Mapping the disease-specific LupusQoL to the SF-6D. <i>Quality of Life Research</i> , 2015 , 24, 1749-58	3.7 10
139	Cognitive dysfunction and functional magnetic resonance imaging in systemic lupus erythematosus. <i>Lupus</i> , 2015 , 24, 1239-47	2.6 18
138	Evaluation of carotid plaque inflammation in patients with active rheumatoid arthritis using (18)F-fluorodeoxyglucose PET-CT and MRI: a pilot study. <i>Lancet, The</i> , 2015 , 385 Suppl 1, S91	40 10

137	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1837-47	9.5	77
136	Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. <i>Arthritis Care and Research</i> , 2015 , 67, 128-35	4.7	31
135	Atherosclerosis in rheumatoid arthritis: is it all about inflammation?. <i>Nature Reviews Rheumatology</i> , 2015 , 11, 390-400	8.1	154
134	The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. <i>Rheumatology</i> , 2015 , 54, 1780-91	3.9	55
133	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. <i>Nature Communications</i> , 2015 , 6, 6046	17.4	103
132	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1530-6	2.4	51
131	Indications for IVIG in rheumatic diseases. <i>Rheumatology</i> , 2015 , 54, 383-91	3.9	39
130	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1706-13	2.4	250
129	Anti-C1q antibodies in systemic lupus erythematosus. <i>Lupus</i> , 2015 , 24, 42-9	2.6	86
128	PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1882-5	2.4	49
127	Clinical features of psoriatic arthritis 2015 , 989-997		
126	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 958-67	2.4	388
125	Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results from the European Prospective Investigation of Cancer-Norfolk and the Norfolk Arthritis Register--the EPIC-2-NOAR Study). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 219-26	2.4	64
124	Changes in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2014 , 66, 1374-9	4.7	38
123	Cell adhesion molecules as potential biomarkers of nephritis, damage and accelerated atherosclerosis in patients with SLE. <i>Lupus</i> , 2014 , 23, 819-24	2.6	23
122	American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. <i>Journal of Rheumatology</i> , 2014 , 41, 875-80	4.1	17
121	N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 684-90	2.4	23
120	Improving cardiovascular outcomes in rheumatic diseases: therapeutic potential of circulating endothelial progenitor cells. <i>Pharmacology & Therapeutics</i> , 2014 , 142, 231-43	13.9	17

119	25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort. <i>Arthritis Care and Research</i> , 2014 , 66, 1167-76	4.7	43
118	Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1144-50	2.4	63
117	The effect of type 1 IFN on human aortic endothelial cell function in vitro: relevance to systemic lupus erythematosus. <i>Journal of Interferon and Cytokine Research</i> , 2014 , 34, 404-12	3.5	9
116	The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease. <i>Lupus</i> , 2014 , 23, 273-83	2.6	17
115	The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2013 , 43, 352-61	5.3	93
114	Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2887-97		65
113	Regulatory T cells in systemic lupus erythematosus and pregnancy. <i>American Journal of Reproductive Immunology</i> , 2013 , 69, 588-95	3.8	8
112	Association of morbid obesity with disability in early inflammatory polyarthritis: results from the Norfolk Arthritis Register. <i>Arthritis Care and Research</i> , 2013 , 65, 122-6	4.7	17
111	Shortened telomere length in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1319-23		30
110	Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. <i>Pharmacogenomics Journal</i> , 2013 , 13, 227-34	3.5	72
109	MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. <i>Pharmacogenomics Journal</i> , 2013 , 13, 137-47	3.5	55
108	Demographic and disease-related predictors of abnormal lung function in patients with established inflammatory polyarthritis and a comparison with the general population. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1517-23	2.4	5
107	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1308-14	2.4	65
106	Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1224-31		56
105	Cardiovascular risk and inflammatory rheumatic diseases. <i>Clinical Medicine</i> , 2013 , 13, 395-7	1.9	7
104	Certolizumab pegol attenuates the pro-inflammatory state in endothelial cells in a manner that is atheroprotective. <i>Clinical and Experimental Rheumatology</i> , 2013 , 31, 225-33	2.2	14
103	Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. <i>Arthritis Care and Research</i> , 2012 , 64, 132-7	4.7	101
102	Endothelial progenitor cells: a new player in lupus?. <i>Arthritis Research and Therapy</i> , 2012 , 14, 203	5.7	13

101	Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal. <i>Pharmacoeconomics</i> , 2012 , 30, 257-70	4.4	28
100	Investigation of IL1, VEGF, PPARG and MEFV genes in psoriatic arthritis susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 313-4	2.4	11
99	The BILAG-2004 systems tally--a novel way of representing the BILAG-2004 index scores longitudinally. <i>Rheumatology</i> , 2012 , 51, 2099-105	3.9	11
98	Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Rheumatology</i> , 2012 , 51, 634-43	3.9	85
97	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2677-86		2688
96	Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: addressing treatment outside the current NICE guidance. <i>Clinical Rheumatology</i> , 2012 , 31, 1005-12	3.9	11
95	25-Hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2012 , 51, 544-51	3.9	70
94	Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1350-4	2.4	31
93	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1502-9	2.4	115
92	Construct and criterion validity of the short form-6D utility measure in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2012 , 39, 735-42	4.1	15
91	Modifiable risk factors for RA: prevention, better than cure?. <i>Rheumatology</i> , 2012 , 51, 499-512	3.9	76
90	An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. <i>Lupus</i> , 2011 , 20, 1459-65	2.6	37
89	Seropositivity is associated with insulin resistance in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register (NOAR): an observational study. <i>Arthritis Research and Therapy</i> , 2011 , 13, R159	5.7	18
88	Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity. <i>Lupus</i> , 2011 , 20, 250-5	2.6	84
87	Cardiovascular risk factors in inflammatory arthritis. <i>Current Opinion in Lipidology</i> , 2011 , 22, 296-301	4.4	16
86	An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 54-9	2.4	68
85	A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. <i>Pharmacogenomics</i> , 2011 , 12, 815-26	2.6	59
84	Reduction of long-term disability in inflammatory polyarthritis by early and persistent suppression of joint inflammation: results from the Norfolk Arthritis Register. <i>Arthritis Care and Research</i> , 2011 , 63, 945-52	4.7	27

83	Decreased live births in women with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2011 , 63, 1068-72	4.7	28
82	Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1726-32	2.4	111
81	SLE and pregnancy: the potential role for regulatory T cells. <i>Nature Reviews Rheumatology</i> , 2011 , 7, 124-8.	1	21
80	Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1016-9	2.4	60
79	Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1641-4	2.4	93
78	Efficiency in follow-up immunology testing for patients with connective tissue diseases and vasculitis. <i>Clinical Medicine</i> , 2011 , 11, 632-3	1.9	1
77	SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 961-7	2.4	39
76	Systemic lupus erythematosus: a pragmatic guide to current management. <i>Rheumatology</i> , 2011 , 50, iii16-iii16	3.9	
75	The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. <i>Rheumatology</i> , 2011 , 50, 982-8	3.9	120
74	Systemic lupus erythematosus, regulatory T cells and pregnancy. <i>Expert Review of Clinical Immunology</i> , 2011 , 7, 635-48	5.1	13
73	Clinical features of psoriatic arthritis 2011 , 1183-1193.e2		1
72	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. <i>Nature</i> , 2010 , 464, 713-20	50.4	639
71	Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. <i>Nature Genetics</i> , 2010 , 42, 996-9	36.3	294
70	Numerical scoring for the BILAG-2004 index. <i>Rheumatology</i> , 2010 , 49, 1665-9	3.9	84
69	The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2010 , 37, 2273-9	4.1	44
68	Risk factors for coronary heart disease in connective tissue diseases. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2010 , 2, 145-53	3.8	10
67	Health-related quality of life, smoking and carotid atherosclerosis in white British women with systemic lupus erythematosus. <i>Lupus</i> , 2010 , 19, 231-8	2.6	14
66	Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 529-35	2.4	184

65	Variants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 2199-203 ^{2.4}	35
64	Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. <i>Journal of Rheumatology</i> , 2010 , 37, 322-9	4.1 65
63	The metabolic syndrome in systemic lupus erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2010 , 36, 81-97, viii	2.4 28
62	EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 2074-82	2.4 462
61	Re-evaluation of biologic therapies in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2010 , 22, 273-7	5.3 18
60	Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2010 , 62, 881-7	4.7 132
59	Numerical scoring for the Classic BILAG index. <i>Rheumatology</i> , 2009 , 48, 1548-52	3.9 31
58	Cardiovascular outcomes in systemic lupus erythematosus: big studies for big questions. <i>Journal of Rheumatology</i> , 2009 , 36, 467-9	4.1 6
57	The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. <i>Rheumatology</i> , 2009 , 48, 691-5	3.9 74
56	Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2009 , 36, 288-94	4.1 26
55	Biomarkers of oxidant stress, insulin sensitivity and endothelial activation in rheumatoid arthritis: a cross-sectional study of their association with accelerated atherosclerosis. <i>BMC Research Notes</i> , 2009 , 2, 83	2.3 26
54	Vitamin D in systemic lupus erythematosus: potential beyond bone health. <i>International Journal of Clinical Rheumatology</i> , 2009 , 4, 297-309	1.5 1
53	BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 873-6	2.4 45
52	A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. <i>PLoS Genetics</i> , 2008 , 4, e1000041	6 503
51	Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. <i>Current Opinion in Lipidology</i> , 2008 , 19, 338-43	4.4 29
50	The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis. <i>Arthritis and Rheumatism</i> , 2008 , 58, 985-9	50
49	Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1784-8	49
48	Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1789-95	15

47	Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2008 , 58, 3705-9		108
46	Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 672-6	2.4	107
45	Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 677-82	2.4	76
44	Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. <i>Arthritis and Rheumatism</i> , 2007 , 56, 265-73		215
43	Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007 , 57, 972-9		185
42	British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007 , 56, 4113-9		76
41	Improved wrist pannus volume measurement from contrast-enhanced MRI in rheumatoid arthritis using shuffle transform. <i>Magnetic Resonance Imaging</i> , 2007 , 25, 110-6	3.3	8
40	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. <i>Nature Genetics</i> , 2007 , 39, 1329-37	36.3	1130
39	Rheumatoid arthritis association at 6q23. <i>Nature Genetics</i> , 2007 , 39, 1431-3	36.3	328
38	Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. <i>Nature</i> , 2007 , 447, 661-78	50.4	7801
37	Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. <i>Nature</i> , 2007 , 450, 887-92	50.4	421
36	Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2007 , 32, 187-95	2.2	97
35	Investigation of association of the DLG5 gene with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 273-4	2.4	0
34	High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. <i>Lupus</i> , 2007 , 16, 387-93	2.6	54
33	HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 807-11	2.4	56
32	Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. <i>Lupus</i> , 2007 , 16, 731-5	2.6	68
31	The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2963-9		82
30	Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. <i>Arthritis and Rheumatism</i> , 2006 , 54, 3300-5		77

29	Systemic lupus erythematosus, eosinophilic vasculitis and acalculous cholecystitis. <i>Nephrology Dialysis Transplantation</i> , 2006 , 21, 792-5	4.3	14
28	Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 1390-3	2.4	19
27	Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2006 , 8, R81	5.7	26
26	Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2006 , 33, 50-6	4.1	78
25	Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005 , 2, 423-30		49
24	Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005 , 19, 823-38	5.3	48
23	Drug efflux transporters in rheumatoid arthritis: comment on the article by Kremer. <i>Arthritis and Rheumatism</i> , 2005 , 52, 670; author reply 672		10
22	Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. <i>Arthritis and Rheumatism</i> , 2005 , 52, 1694-9		239
21	Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3596-602		60
20	Atherogenesis and autoimmune disease: the model of lupus. <i>Lupus</i> , 2005 , 14, 687-90	2.6	35
19	Not only...but also factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. <i>Rheumatology</i> , 2005 , 44, 1492-502	3.9	217
18	Prolonged remission in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2005 , 32, 1467-72	4.1	76
17	Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. <i>Circulation</i> , 2004 , 110, 399-404	16.7	214
16	Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. <i>Arthritis and Rheumatism</i> , 2003 , 48, 3159-67		271
15	Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2003 , 62, 15-9	2.4	30
14	Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome. <i>Clinical Infectious Diseases</i> , 2003 , 36, e100-6	11.6	50
13	Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. II. Predictive factors for perfusion abnormalities. <i>Journal of Rheumatology</i> , 2003 , 30, 288-91	4.1	25
12	Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2002 , 61, 1007-11	2.4	64

11	Genetic epidemiology: systemic lupus erythematosus. <i>Arthritis Research</i> , 2001 , 3, 331-6		16
10	Hyperuricemia in Psoriatic Arthritis. <i>Journal of Clinical Rheumatology</i> , 2000 , 6, 6-9	1.1	35
9	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. <i>Arthritis and Rheumatism</i> , 2000 , 13, 406-408		44
8	Atherosclerosis and systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2000 , 2, 19-23	4.9	27
7	Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud's phenomenon. <i>Annals of the Rheumatic Diseases</i> , 2000 , 59, 870-4	2.4	30
6	Premature atherosclerosis in systemic lupus erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2000 , 26, 257-78	2.4	101
5	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence 2000 , 13, 406		3
4	Factors associated with fatigue in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 1999 , 58, 379-81	2.4	88
3	Psoriatic arthritis: recognition and management. <i>BioDrugs</i> , 1998 , 9, 271-8	7.9	10
2	An audit of ANCA in routine clinical practice. <i>Postgraduate Medical Journal</i> , 1995 , 71, 605-12	2	14
1	The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans. <i>European Journal of Clinical Investigation</i> , 1994 , 24, 759-65	4.6	49